RGX-019 is an investigational drug candidate. Rgenix is developing RGX-019, a monoclonal antibody that targets MerTK, for the treatment of solid tumors. Rgenix in-licensed RGX-019 and other antibody intellectual property from Rockefeller University as part of a world-wide exclusive licensing agreement.
Rgenix identified MerTK as a novel cancer target in triple-negative breast cancer (TNBC) in collaboration with the Rockefeller University by using the company’s proprietary target discovery platform.1 MerTK is a receptor tyrosine kinase of the TAM family and is over-expressed in several human cancers.2 The MerTK pathway drives cancer progression, tumor angiogenesis, and innate immune activation2,3 Targeting MerTK affects tumor associated macrophage polarization in part by changing them from a pro-tumorigenic M2 state to an anti-tumorigenic M1 state. Rgenix plans to initiate IND-enabling studies of RGX-019 in 2019.
RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.